SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling

Nature Communications
Thomas StrubEmily Bernstein

Abstract

While multiple mechanisms of BRAFV600-mutant melanoma resistance to targeted MAPK signaling inhibitors (MAPKi) have been reported, the epigenetic regulation of this process remains undetermined. Here, using a CRISPR-Cas9 screen targeting chromatin regulators, we discover that haploinsufficiency of the histone deacetylase SIRT6 allows melanoma cell persistence in the presence of MAPKi. Haploinsufficiency, but not complete loss of SIRT6 promotes IGFBP2 expression via increased chromatin accessibility, H3K56 acetylation at the IGFBP2 locus, and consequent activation of the IGF-1 receptor (IGF-1R) and downstream AKT signaling. Combining a clinically applicable IGF-1Ri with BRAFi overcomes resistance of SIRT6 haploinsufficient melanoma cells in vitro and in vivo. Using matched melanoma samples derived from patients receiving dabrafenib + trametinib, we identify IGFBP2 as a potential biomarker for MAPKi resistance. Our study has not only identified an epigenetic mechanism of drug resistance, but also provides insights into a combinatorial therapy that may overcome resistance to standard-of-care therapy for BRAFV600-mutant melanoma patients.

References

Mar 1, 1988·Experimental Cell Research·N P SinghE L Schneider
Jan 28, 2004·Journal of Cutaneous Pathology·Huamin WangVictor G Prieto
May 14, 2004·Pigment Cell Research·M Stefania LagonigroManuela Gariboldi
Jan 28, 2006·Cell·Raul MostoslavskyFrederick W Alt
Feb 3, 2007·Current Opinion in Oncology·Jedd D Wolchok, Yvonne M Saenger
Mar 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Christine A PratilasNeal Rosen
Mar 6, 2009·Genome Biology·Ben LangmeadSteven L Salzberg
Jan 19, 2010·Annual Review of Pathology·Marcia C Haigis, David A Sinclair
Feb 17, 2010·The Journal of Clinical Endocrinology and Metabolism·Jyh-Ming LiouJaw-Town Lin
Jul 22, 2010·Cancer Research·Yongping Shao, Andrew E Aplin
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Sep 10, 2010·Methods in Molecular Biology·Alessia Baccarini, Brian D Brown
Nov 23, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chen Chen JiangXu Dong Zhang
Mar 1, 2011·Current Biology : CB·Alessia BaccariniBrian D Brown
Sep 14, 2011·Journal of Biomedicine & Biotechnology·Ramkumar RajendranConstantinos Demonacos
Oct 15, 2011·Current Oncology Reports·Moriah H Nissan, David B Solit
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Sep 18, 2012·Cell·Christine Guo LianYujiang G Shi
Oct 23, 2012·Nature Medicine·Nagalingam R SundaresanMahesh P Gupta
Oct 30, 2012·Bioinformatics·Alexander DobinThomas R Gingeras
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Apr 17, 2013·BMC Bioinformatics·Edward Y ChenAvi Ma'ayan
May 7, 2013·Nature Structural & Molecular Biology·Dan HassonBen E Black
Aug 21, 2013·Cancer Research·Miguel F SeguraEva Hernando
Nov 10, 2013·Nature Medicine·Piro LitoDavid B Solit
Dec 18, 2013·Science·Ophir ShalemFeng Zhang
Jan 28, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helen RizosGeorgina V Long
Feb 4, 2014·Genome Biology·Charity W LawGordon K Smyth
Aug 1, 2014·Genome Research·Simone PicelliRickard Sandberg
Dec 2, 2014·Nature Reviews. Drug Discovery·Ahmed A Samatar, Poulikos I Poulikakos
Dec 30, 2014·Cytokine & Growth Factor Reviews·V C RussoG A Werther

❮ Previous
Next ❯

Citations

Jun 30, 2019·Cell Cycle·Luis Filipe Costa-Machado, Pablo J Fernandez-Marcos
Aug 23, 2019·Physiological Reviews·Andrew R ChangRaul Mostoslavsky
Oct 5, 2019·Cancers·Mehwish Khaliq, Mohammad Fallahi-Sichani
Nov 8, 2019·Experimental Dermatology·Liz M Garcia-PetersonNihal Ahmad
Jun 22, 2019·Nature Communications·Charles C BellMark A Dawson
Jul 2, 2020·International Journal of Molecular Sciences·Anna M CzarneckaPiotr Rutkowski
Feb 20, 2019·Current Treatment Options in Oncology·Chi-Che Hsieh, Che-Hung Shen
Apr 3, 2020·International Journal of Oncology·Florencia Paula Madorsky RowdoJosé Mordoh
Feb 13, 2020·International Journal of Molecular Sciences·Shannon LeeWalter Kolch
Dec 17, 2020·Medicinal Research Reviews·Gang LiuJia Zhou
Jan 28, 2021·International Journal of Molecular Sciences·Hatim BoughanemManuel Macias-Gonzalez
Nov 23, 2020·Journal of Cancer Research and Clinical Oncology·Fubo WangRui Chen
Jan 13, 2021·Cancers·Aranka BrockmuellerMehdi Shakibaei
Feb 6, 2021·Cancer Cell·E Elizabeth PattonGlenn Merlino
Mar 16, 2019·Current Opinion in Chemical Biology·Tatsiana KosciukHening Lin
Jul 7, 2020·Neoplasia : an International Journal for Oncology Research·Florina GrigoreJames P Robinson
Mar 27, 2021·Frontiers in Cell and Developmental Biology·Soudeh Ghafouri-FardMohammad Taheri
Mar 31, 2021·The Journal of Investigative Dermatology·Abdullah Al EmranJessamy C Tiffen
Apr 4, 2021·Cancers·Francesco FiorentinoDante Rotili
Jun 3, 2021·International Journal of Molecular Sciences·Iwona KarwaciakMarcin Ratajewski
May 5, 2021·The Journal of Clinical Investigation·William GiblinDavid B Lombard
Jul 3, 2021·Cancers·Hyuk Moon, Simon Weonsang Ro
Aug 28, 2021·Cells·Emilio Francesco Giunta On Behalf Of Scito Youth
Sep 3, 2021·Developmental Cell·Meng-Yen LiElena Ezhkova
Sep 18, 2021·Cancer Research·Narendra Wajapeyee, Romi Gupta

❮ Previous
Next ❯

Methods Mentioned

BETA
histone acetylation
biopsies
xenograft
xenografts
acetylation
RNA-seq
ChIP-seq
Protein Array
electrophoresis
flow cytometry

Software Mentioned

Bowtie2
house
CellProfiler
Cluster
Bowtie
GraphPad
- tools
voom
Treeview
samtools

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Screens in Drug Resistance (ASM)

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
Madeleine S Q KortenhorstShabana Shabbeer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Xiaofeng JiangF Stephen Hodi
© 2022 Meta ULC. All rights reserved